HRMY Q2 2023 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$134M+25.4% YoY

Gross Profit

$109M81.4% margin

Operating Income

$47M34.9% margin

Net Income

$34M25.6% margin

EPS (Diluted)

$0.56

QoQ Revenue Growth

+12.7%

Cash Flow

Operating Cash Flow

$37M

Free Cash Flow

$37M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$760M

Total Liabilities

$275M

Stockholders' Equity

$485M

Cash & Equivalents

$317M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$134M	$107M	+25.4%
Gross Profit	$109M	$88M	+23.9%
Operating Income	$47M	$33M	+41.6%
Net Income	$34M	$24M	+45.8%

Geographic Segments

United States

$500M100%